“Invitro” starts to perform tests for coronavirus infection COVID-19 as a centralized laboratory. The first tests begins to perform laboratory complex in Novosibirsk. The laboratory will make the biological material from state medical institutions, clinics and hospitals. The first clinical samples for research will arrive within this week.
Earlier it was reported that a test for the coronavirus can be passed in a medical office network “in vitro”. However, after analyzing the situation and assessing all possible risks to the health of patients and staff, the company decided to focus on working with government health agencies. Analysis of coronavirus infection can be taken at the clinic by place of residence, the containers with biological material will be in accordance with all the rules of Biosafety transferred to the laboratory complex “in vitro” in Novosibirsk. The duration of study is 1 day.
Novosibirsk laboratory “Invitro” got a test system of the Russian producer JSC “Vector-best”. The test system has high sensitivity of detection of RNA of the coronavirus SARS-CoV-2 – 1×10*3 copies/ml of the original sample and specificity of 100 %. To assess analytical specificity of the manufacturer’s tests were conducted with potentially interfering viruses (influenza A and b, parainfluenza, adenovirus infection, respiratory syncytial infection, metapneumovirus infection, rhinovirus infection and coronavirus infection of man, caused by hCov NL63, hCov OC43, hCov 229E, hCov HKUI) and microorganisms (Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus). Cross-reacting viruses and microorganisms were found.